Table 2.
Patient characteristics by serum ferritin in US DOPPS (2009–15)
| Patient characteristic | All | Serum ferritin (ng/mL) |
||||
|---|---|---|---|---|---|---|
| <200 | 200–499 | 500–799 | 800–1199 | ≥1200 | ||
| Patients, n (%) | 8510 | 666 (8) | 1910 (22) | 2316 (27) | 2261 (27) | 1357 (16) |
| Demographics | ||||||
| Age (years), mean ± SD | 62.4 ± 15.1 | 59.1 ± 15.9 | 60.7 ± 15.1 | 62.2 ± 14.8 | 63.4 ± 14.9 | 65.1 ± 14.8 |
| Sex (male), % | 56 | 63 | 60 | 56 | 53 | 51 |
| Race (black), % | 32 | 25 | 32 | 32 | 34 | 35 |
| Vintage (years), mean ± SD | 3.6 ± 3.9 | 3.2 ± 4.2 | 2.9 ± 3.7 | 3.5 ± 3.9 | 4.1 ± 3.9 | 4.2 ± 4.0 |
| HD characteristics | ||||||
| Catheter use, % | 28 | 39 | 38 | 28 | 22 | 22 |
| Single pool Kt/V, mean ± SD | 1.54 ± 0.31 | 1.49 ± 0.35 | 1.47 ± 0.32 | 1.53 ± 0.31 | 1.58 ± 0.28 | 1.60 ± 0.29 |
| Anemia treatments (past 3–4 months) | ||||||
| IV iron (with any dose), % | 77 | 64 | 82 | 80 | 77 | 72 |
| IV iron (mg/week) among treated, mean ± SD | 75 ± 52 | 74 ± 50 | 72 ± 49 | 68 ± 46 | 75 ± 51 | 94 ± 62 |
| Bolusa dose of IV iron among treated, % | 38 | 41 | 35 | 32 | 39 | 52 |
| ESA (with any dose), % | 93 | 84 | 93 | 94 | 93 | 94 |
| ESA (1000 units/week) among treated, mean ± SD | 15 ± 15 | 22 ± 20 | 16 ± 15 | 15 ± 14 | 13 ± 14 | 14 ± 15 |
| Transfused, % | – | – | – | – | – | – |
| Anemia labs, mean ± SD | ||||||
| Ferritin (ng/mL) | 774 ± 467 | 119 ± 54 | 363 ± 84 | 650 ± 86 | 975 ± 112 | 1, 552 ± 417 |
| TSAT (%) | 31.3 ± 12.7 | 24.6 ± 11.2 | 28.8 ± 11.2 | 30.9 ± 11.5 | 33.1 ± 12.7 | 36.0 ± 15.0 |
| Hemoglobin (g/dL) | 11.2 ± 1.2 | 11.5 ± 1.5 | 11.4 ± 1.2 | 11.2 ± 1.1 | 11.0 ± 1.2 | 10.9 ± 1.2 |
| Nutrition and inflammation markers, mean ± SD | ||||||
| Body mass index (kg/m2) | 28.7 ± 7.0 | 28.9 ± 6.6 | 28.9 ± 7.0 | 28.8 ± 7.2 | 28.7 ± 7.1 | 28.0 ± 6.8 |
| Normalized PCR (g/kg/day) | 0.95 ± 0.26 | 0.91 ± 0.26 | 0.93 ± 0.26 | 0.95 ± 0.26 | 0.97 ± 0.25 | 0.97 ± 0.26 |
| Serum phosphorus (mg/dL) | 5.2 ± 1.5 | 5.3 ± 1.5 | 5.2 ± 1.5 | 5.2 ± 1.5 | 5.1 ± 1.4 | 5.1 ± 1.5 |
| Serum bicarbonate (mEq/L) | 23.6 ± 3.3 | 23.3 ± 3.4 | 23.3 ± 3.2 | 23.5 ± 3.3 | 23.7 ± 3.3 | 23.9 ± 3.3 |
| Serum potassium (mEq/L) | 4.7 ± 0.7 | 4.7 ± 0.7 | 4.7 ± 0.7 | 4.7 ± 0.7 | 4.8 ± 0.6 | 4.7 ± 0.7 |
| Serum creatinine (mg/dL) | 8.2 ± 3.1 | 8.1 ± 3.2 | 8.2 ± 3.1 | 8.2 ± 3.1 | 8.3 ± 2.9 | 8.2 ± 3.1 |
| Serum albumin (g/dL) | 3.84 ± 0.40 | 3.79 ± 0.42 | 3.84 ± 0.40 | 3.86 ± 0.39 | 3.87 ± 0.40 | 3.81 ± 0.43 |
| WBC count (1000 cells/mm3) | 6.9 ± 2.3 | 6.8 ± 2.3 | 6.7 ± 2.1 | 6.8 ± 2.1 | 7.1 ± 2.3 | 7.4 ± 2.5 |
| CRP (mg/L) | – | – | – | – | – | – |
| Hospitalized in past 3–4 months, % | 16 | 19 | 17 | 14 | 15 | 19 |
| Comorbid conditions, % | ||||||
| Coronary artery disease | 32 | 32 | 31 | 33 | 31 | 30 |
| Congestive heart failure | 33 | 34 | 34 | 34 | 33 | 32 |
| Cerebrovascular disease | 10 | 9 | 9 | 9 | 10 | 11 |
| Peripheral vascular disease | 17 | 17 | 17 | 18 | 18 | 17 |
| Other cardiovascular disease | 17 | 19 | 16 | 17 | 16 | 17 |
| Hypertension | 81 | 84 | 80 | 80 | 82 | 82 |
| Diabetes | 61 | 56 | 62 | 63 | 62 | 58 |
| Neurologic disease | 7 | 8 | 7 | 7 | 7 | 8 |
| Psychiatric disorder | 13 | 17 | 12 | 13 | 12 | 13 |
| Lung disease | 11 | 13 | 12 | 11 | 11 | 11 |
| Cancer (non-skin) | 8 | 7 | 7 | 7 | 9 | 11 |
| Gastrointestinal bleeding | 3 | 3 | 3 | 3 | 3 | 4 |
| Recurrent cellulitis, gangrene | 8 | 8 | 9 | 8 | 8 | 5 |
Data on transfusions and CRP were not available in the USA.
a
Defined as at least 1 month (of prior 3–4 months) with IV iron dose ≥500 mg.